OncoMatch/Clinical Trials/NCT05027776
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Is NCT05027776 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including 2-doses Group among 9-14 years and 3-doses Group among 9-19 years for hpv infections.
Treatment: 2-doses Group among 9-14 years · 3-doses Group among 9-19 years · 3-doses Group among 20-26 years — This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA
Cervical Cancer Stage IIa
Prior therapy
Cannot have received: HPV vaccine
Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials
Cannot have received: immune globulin or blood-related products
Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period（month 0 to month 7）
Cannot have received: immunosuppressive treatment (long-term glucocorticoid)
Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7
Cannot have received: inactivated, RNA, and recombinant vaccines
Receipt of inactivated, RNA, and recombinant vaccines within 14 days
Cannot have received: live vaccines
live vaccines within 28 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify